Navigation Links
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Date:2/5/2009

MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA).

The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for the agent when administered orally in capsule form every two weeks to patients with a diverse range of solid tumors. Safety and tolerability data from this study augments data obtained in the company's first Phase I study where CYT997 was administered intravenously. Together, these studies suggest that the CYT997 is a potent and selective VDA which is well tolerated at biologically efficacious doses and is worthy of further investigation as a novel anticancer agent.

"Cytopia has now demonstrated the broad clinical potential of CYT997 in both intravenous and oral forms," said Mr. Andrew Macdonald, CEO. "The oral activity of CYT997 is a key advantage over most other vascular disrupting agents which are administered intravenously. The oral activity of the agent should markedly improve its clinical and commercial value."

The company has already commenced Phase II studies for the intravenous form of CYT997 and intends to undertake similar efficacy studies for the oral presentation. Investigating the safety and efficacy of metronomic dosing, frequent oral administration at a comparatively low, but biologically effective dose, is of particular interest.

This oral trial was partly funded under the company's $A3 million Commercial Ready grant.

Preliminary trial data

CYT997 was generally well tolerated in this study with a maximum tolerated dose in cancer patients of ca 165 mg/m2. This dose resulted in maximal plasma concentrations some twofold higher than those obse
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytopia Scientific Presentations on JAK2 Inhibitor Program
2. Cytopia Commences Second Phase II Study in Brain Cancer
3. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
4. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
5. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
6. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
7. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
8. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
11. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... Aug. 5 ViroPharma Incorporated (Nasdaq: ... of Cinryze™ (C1 esterase inhibitor [human]) have been published in the ... Journal of Medicine .  The paper entitled Nanofiltered C1 Inhibitor ... L. Zuraw et al. describes the safety and ...
... to provide physical therapy and prosthetic limbs , ... WASHINGTON , Aug. 4 The Knights of Columbus today ... a limb in the January earthquake that destroyed much of their country and claimed ... hundreds of children who lost arms and legs in the tragedy. , ...
Cached Medicine Technology:ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine 2ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine 3ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine 4ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine 5ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine 6ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine 7ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine 8ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine 9New Program Makes Prosthetics Available to All Haitian Children Who Lost Limbs in Earthquake 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... 4 Judie Brown, president of American ... to an interview in which Archbishop Raymond Burke, ... court, stated: (Logo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) "There,s not ... after admonition, supports pro-abortion legislation is not to ...
... Inc. (Nasdaq: IDEV ) (the "Company") today announced ... fiscal 2009, ended December 31, 2008. The Company reported revenues ... million or $0.10 per share for the quarter ended December ... and a consolidated net loss of $14.7 million or $0.19 ...
... Rev. Larry Snyder, president of Catholic Charities ... the East Room of the White House as the ... Reauthorization Act of 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20081008/CCUSALOGO )The ... care access to children whose families do not qualify ...
... The Elton John AIDS Foundation announced today that ... Annual Elton John AIDS Foundation (EJAF) Academy Awards(R) Viewing ... Design Center in Los Angeles. The event will be ... will be co-sponsored by Chopard, Jo & Raffy Manoukian, ...
... Holdings, Inc.,(NYSE: HRC ), announced unaudited ... 31, 2008. Results included revenue of $351.6 ... $341.4 million in the prior year,comparable period. On ... Net income from continuing operations was $14.2 million, ...
... Tax Little Cigars at Cigarette Equivalent for First TimeWASHINGTON, ... indicates a dramatic increase in the use of cigarillos ... trend given the popularity of these products with young ... According to the data, over a 10-year period from ...
Cached Medicine News:Health News:American Life League: Vatican Says Bishops Must Refuse Communion to Pro-Abortion Politicians 2Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 2Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 3Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 4Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 5Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 6Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 7Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 8Health News:Catholic Charities USA President Joins President Obama at Signing of Children's Health Insurance Legislation 2Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 2Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 3Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 4Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 2Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 3Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 4Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 5Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 6Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 7Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 8Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 9Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 10Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 11Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 12Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 13Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 14Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 2Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 3Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 4
Electric high speed system....
Compressor-cooled plate used to keep blocks cold while sectioning....
... CO-Oximeter Control (Bayer 800 Series) is ... monitoring the performance of blood gas, ... 270 and 800 series) instrumentation. This ... Bayer 800 Rapidlab Series instruments in ...
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: